It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Autophagy is an important biological process in normal cells. However, how it affects tumor progression still remains poorly understood. Herein, we demonstrated that the oncogenic protein Chromodomain-helicase-DNA-binding-protein 1-like gene (CHD1L) might promote HCC cells migration and metastasis through autophagy. CHD1L could bind to the promotor region of Zinc finger with KRAB and SCAN domain 3 (ZKSCAN3), a pivotal autophagy suppressor, and inhibit its transcription. We established inducible CHD1L conditional knockout cell line (CHD1L-iKO cell) and found that the deletion of CHD1L significantly increased ZKSCAN3 expression both at mRNA and protein level. Deletion of CHD1L impaired the autophagic flux and migration of HCC cells, while specifically inhibiting ZKSCAN3 blocked these effects. Further exploration demonstrated that the enhanced tumor cell migration and metastasis induced by CHD1L was mediated through ZKSCAN3-induced autophagic degradation of Paxillin. In summary, we have characterized a previously unknown function of CHD1L in regulating tumor migration via ZKSCAN3-mediated autophagy in HCC. Further inhibition of CHD1L and its downstream autophagy signaling might shed new light on cancer therapeutics.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details




1 Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072); School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou Municipal and Guangdong ProvincialKey Laboratory of Protein Modification and Degradation, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072)
2 School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou Municipal and Guangdong ProvincialKey Laboratory of Protein Modification and Degradation, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072); Foshan University, School of Life Science and Engineering, Foshan, China (GRID:grid.443369.f) (ISNI:0000 0001 2331 8060)
3 School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou Municipal and Guangdong ProvincialKey Laboratory of Protein Modification and Degradation, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072)
4 Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072)
5 Qingyuan People’s Hospital, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072)
6 Sun Yat-sen University, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Cancer Center, Guangzhou, China (GRID:grid.12981.33) (ISNI:0000 0001 2360 039X); University of Hong Kong, Department of Clinical Oncology, Center for Cancer Research, and State Key Laboratory for Liver Research, Pok Fu Lam, Hong Kong (GRID:grid.194645.b) (ISNI:0000000121742757)
7 Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072); School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou Municipal and Guangdong ProvincialKey Laboratory of Protein Modification and Degradation, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072); Guangzhou Medical University, Department of Histology and Embryology, School of Basic Medical Sciences, Guangzhou, China (GRID:grid.410737.6) (ISNI:0000 0000 8653 1072)